Document Detail

Early detection and management of pulmonary arterial hypertension.
MedLine Citation:
PMID:  23204118     Owner:  NLM     Status:  MEDLINE    
The long-term prognosis for patients with pulmonary arterial hypertension (PAH) remains poor, despite advances in treatment options that have been made in the past few decades. Recent evidence suggests that World Health Organization functional class I or II patients have significantly better long-term survival rates than patients in higher functional classes, thus providing a rationale for earlier diagnosis and treatment of PAH. However, early diagnosis is challenging and there is frequently a delay between symptom onset and diagnosis. Screening programmes play an important role in PAH detection and expert opinion favours echocardiographic screening of asymptomatic patients who may be predisposed to the development of PAH (i.e. those with systemic sclerosis or sickle cell disease), although current guidelines only recommend annual echocardiographic screening in symptomatic patients. This article reviews the currently available screening programmes, including their limitations, and describes alternative screening approaches that may identify more effectively those patients who require right heart catheterisation for a definitive PAH diagnosis.
Marc Humbert; J Gerry Coghlan; Dinesh Khanna
Related Documents :
22722728 - Perceptions among primary caregivers about the etiology of delirium: a study from a ter...
2718228 - Proper positioning eliminates patient injury.
24791928 - The veines-qol/sym questionnaire is a reliable and valid disease-specific quality of li...
11762268 - Neuromuscular-blocking drugs. use and misuse in the intensive care unit.
9186198 - Extracorporeal life support for patients with significant orthopaedic trauma.
22390918 - Re-building life after icu: a qualitative study of the patients' perspective.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  European respiratory review : an official journal of the European Respiratory Society     Volume:  21     ISSN:  1600-0617     ISO Abbreviation:  Eur Respir Rev     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-03     Completed Date:  2013-05-24     Revised Date:  2013-06-18    
Medline Journal Info:
Nlm Unique ID:  9111391     Medline TA:  Eur Respir Rev     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  306-12     Citation Subset:  IM    
Université Paris-Sud, AP-HP, Service de Pneumologie, Hôpital Bicêtre, Inserm U999, Le Kremlin Bicêtre, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anemia, Sickle Cell / complications
Antihypertensive Agents / therapeutic use
Early Diagnosis*
Echocardiography, Doppler
Exercise Test
Hypertension, Pulmonary / classification,  diagnosis*,  drug therapy*
Mass Screening
Natriuretic Peptide, Brain / analysis
Peptide Fragments / analysis
Piperazines / therapeutic use
Practice Guidelines as Topic
Purines / therapeutic use
Respiratory Function Tests
Risk Factors
Scleroderma, Systemic / complications
Sulfonamides / therapeutic use
Sulfones / therapeutic use
Vasodilator Agents / therapeutic use
Reg. No./Substance:
0/Antihypertensive Agents; 0/Peptide Fragments; 0/Piperazines; 0/Purines; 0/Sulfonamides; 0/Sulfones; 0/Vasodilator Agents; 0/pro-brain natriuretic peptide (1-76); 114471-18-0/Natriuretic Peptide, Brain; 3M7OB98Y7H/sildenafil; Q326023R30/bosentan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A robust procedure for distinctively visualizing zebrafish retinal cell nuclei under bright field li...
Next Document:  Challenges in the diagnosis and treatment of pulmonary arterial hypertension.